Regulatory Milestone
Lord’s Mark Industries Limited announced that its in‑vitro diagnostics (IVD) portfolio received registration from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) on 24 September 2026. The registration lists the company as a registered manufacturer and covers several IVD categories, namely haematological cell analysers, chemistry analysers, buffered sample diluents and instrument/analyser cleaning agents.
Prior Approval and Strategic Context
This regulatory achievement follows the company’s earlier MHRA registration for its AI‑powered Renalyx haemodialysis system, which was disclosed in September 2026 and marked the firm’s intended entry into the UK and allied markets. The successive approvals broaden Lord’s Mark’s roadmap from renal‑care technology to a wider diagnostics offering, laying the groundwork for an integrated healthcare platform in the region.
Commercialisation Timeline
Lord’s Mark plans to commence commercial sales of the newly registered IVD products in the United Kingdom in December 2026, which is approximately two months earlier than the originally projected schedule. In addition, the company intends to launch operations of its own pathology laboratory in January 2027, creating a complementary service platform for diagnostic testing and supporting the broader vision of combining diagnostic products, laboratory capabilities and healthcare delivery.
Market Strategy and Expansion Intent
The firm views the UK market as a pivotal international platform and will pursue further opportunities across UK‑allied jurisdictions, subject to meeting each jurisdiction’s specific regulatory requirements. By aligning product registration, early market entry, and the establishment of a pathology lab, Lord’s Mark is positioning its UK expansion as an integrated healthcare strategy rather than a single‑product launch.
Executive Commentary
Dr. Sachidanand Upadhyay, MD & CEO of Lord’s Mark Industries Limited, stated: “Our recent MHRA registration for the Renalyx haemodialysis system opened an important door for us in the UK & UK‑allied markets. This latest registration for our IVD portfolio demonstrates that our ambition extends well beyond a single healthcare product. We are building a broader diagnostics and healthcare platform, with commercialisation now planned two months ahead of schedule, followed by the launch of our pathology laboratory in January 2027.”